“The Global Difficult-to-Express Proteins Market is predicted to reach a high CAGR during the forecast period (2021-2028).”
Difficult-to-express proteins are the proteins whose synthesis is difficult in conventional in vivo protein production platforms. Moreover, it is often challenging to express these proteins in heterologous expression systems due to their inherent properties, the tendency to aggregate and form inclusion bodies, intrinsic nature, and difficultly for the foreign host to fold a protein correctly. The special type of proteins such as membrane proteins, antibody types, proteases, kinases, and others are difficult-to-express proteins.
Download free sample: https://www.datamintelligence.com/download-sample/difficult-to-express-proteins-market
The market growth is driven by the rising manufacturing of recombinant proteins for producing complex therapeutics. There is an increase in the research and development activities for the development of difficult-to-express proteins therapeutics due to their properties such as solubility, immunogenicity, and bioactivity when expressed in mammalian cells.
The market is witnessing the development of novel cell-free protein synthesis platforms based on the industrial working horse CHO cells that overcome the issues. For instance, In March 2019, Catalent had launched its next-generation cell line development technology i.e., GPEx Boost to enhance the GPEx expression platform through multiple improvements, including utilization of glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of both technology and platform enhancements would result in the cell’s improved ability to produce high titers and increase specific protein productivities of interest.
In March 2019, ExcepGed launched Y Combinator with technology that uses an engineered human cell line to produce full-length human proteins for drug discovery. This platform would be used to rapidly express proteins in mammalian cells with the potential to successfully express these larger proteins.
There is an increase in the development of several techniques such as different expression systems, promoters, cultivation media, and condition, chaperone coexpression, solubilization ta, gs, others for producing and purifying difficult-to-express proteins. However, the high cost of systems and difficulty in analyzing target is expected to hinder the market growth.
Cell-free Protein Synthesis
Prokaryotic Expression Systems
SUMO Fusion System
Gene Fusion Systems
Disease Diagnostics and Monitoring
By region, the difficult-to-express proteins market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East and Africa. Among all of the regions, the North America region dominated the difficult-to-express proteins market due to increasing research and development activities for the development of different technologies for the synthesis of difficult-to-express proteins. Several companies are entering into the collaborations with the other companies, organizations, and institutes for developing the products related to difficult-to-express proteins. It is further expected that the North America region would maintain its dominant position over the forecasted period.
Europe is expected to have a significant market share owing to the increasing investment from the government and non-government organizations. The growing prevalence of chronic disease shall stimulate market growth. Chronic diseases are the leading cause of mortality and morbidity in European Countries. The burden of developing chronic diseases such as cardiovascular disease, diabetes, asthma, chronic obstructive pulmonary disease (COPD), HIV/AIDS, mental disorder, and others increases aging populations. According to Eurostat, age-group of aged 65 and more accounts for one-fifth, i.e., 19 % of the European population.
The difficult-to-express proteins market is highly competitive with the product diversification, revenue generation, and opportunities. Several local and international players are present in the market. R&D Systems, Bio-Rad Laboratories, Enzo Life Sciences, Sino Biological, Thermo Fisher Scientific, StressMarq Biosciences, and Lucigen are the leading market players with significant market share.
Companies are focusing on new product launches, technological advancement, product diversification, market expansion, and market penetration strategies for strengthening their position in the market. They are conducting research and development activities for developing difficult-to-express proteins with innovation and diversification. For instance, In May 2019, Catalent had launched its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologics. One Bio would help in addressing the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework.